Envirotech Vehicles appoints Jason Maddox to board of directors
On Tuesday, UBS analysts reaffirmed their Neutral rating for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN), maintaining a price target of $633.00. The decision follows recent developments in Regeneron’s obesity treatment pipeline. Trading near its 52-week low of $481.58, the stock has seen a sharp 18.6% decline in the past week. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting targets ranging from $535 to $950.
The company released an interim report that UBS analysts consider a minor positive for the sector. This update underscores Regeneron’s potential in the obesity treatment space, which may be undervalued by the market. With a P/E ratio of 11.81 and robust gross margins of 48.8%, Regeneron maintains strong fundamentals. For deeper insights into Regeneron’s valuation and 12+ exclusive ProTips, consider exploring InvestingPro.
Alongside the report, Regeneron announced a licensing agreement for a Phase 3 GLP-1/GIP receptor agonist from a Chinese biotech firm. The agreement involves an upfront payment of $80 million, and the therapy could complement Regeneron’s existing treatments, including their anti-mstn/activin and leptin receptor agonist combinations.
UBS analysts believe these developments highlight Regeneron’s strategic moves to strengthen its pipeline in obesity therapies. The firm continues to see potential in Regeneron’s treatments, reflected in the maintained price target and Neutral rating.
In other recent news, Regeneron Pharmaceuticals has been the focus of multiple analyst assessments and company developments. Regeneron’s recent Phase 3 trials for itepekimab in chronic obstructive pulmonary disease (COPD) have drawn attention, with only one of the two studies meeting the primary endpoint. This has led Bernstein SocGen Group to lower the price target for Regeneron to $750 from $896, although they maintain an Outperform rating. In a different vein, TD Cowen analysts remain optimistic, reiterating their Buy rating with a price target of $800, following positive Phase III trial results for Libtayo in treating adjuvant high-risk cutaneous squamous cell carcinoma (CSCC).
Meanwhile, RBC Capital maintains a Sector Perform rating with a $662 price target, focusing on the potential of trevogrumab for obesity treatment, despite market challenges. BMO Capital also holds an Outperform rating, highlighting Regeneron’s recent licensing of HS-20094, a GLP-1/GIP receptor agonist, with promising Phase 2 data showing improved weight loss. Truist Securities continues to support a Buy rating, albeit with caution due to mixed results for itepekimab and ongoing challenges for Eylea. These developments reflect both the opportunities and hurdles Regeneron faces as it navigates a complex and competitive pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.